戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ospitalized patients that involve a clinical hematologist.
2 written from the perspective of a practicing hematologist.
3 otable therapeutic challenge to the clinical hematologist.
4 rpretation from a radiation oncologist and a hematologist.
5 mbocythemia, presents many challenges to the hematologist.
6 a when treatment was directed by a pediatric hematologist.
7 ght chain (AL) amyloidosis is a challenge to hematologists.
8 t-related disorders of potential interest to hematologists.
9 ntinued in the ICU under the guidance of the hematologists.
10  problem seen by primary care physicians and hematologists.
11 and ubiquitin biology fields as well as from hematologists.
12 ic physicians, rheumatologists, and clinical hematologists.
13 ticipants were oncologists (36.1%; n = 239), hematologists (14.5%; n = 96), radiation oncologists (7.
14 dents included oncologists (38.5%, n = 371), hematologists (16.4%, n = 158), radiation oncologists (9
15 39 physicians); 37% were medical oncologists/hematologists, 50% were radiation oncologists, and 12% w
16 dical directors of blood banks (3 patients), hematologists (6), and the manufacturer of clopidogrel (
17 am that includes a hematologist, a pediatric hematologist, a clinical geneticist, an obstetrician-per
18 linary approach, with a team that includes a hematologist, a pediatric hematologist, a clinical genet
19 py before focusing on a frequent question to hematologists about the 2 most commonly used antiplatele
20                Familiar to nephrologists and hematologists alike, classically associated with thrombo
21                           Here, 2 experts, a hematologist and a hospitalist, reflect on the care of a
22  to orchestrate processes of interest to the hematologist and more broadly.
23 ality collaboration between intensivists and hematologists and all crossdisciplinary health care work
24 ty of Hematology convened an expert panel of hematologists and forensic pathologists to conduct a sys
25  Our tool can be potentially used by general hematologists and health care providers not specialized
26           This paper is of broad interest to hematologists and immunologists as it illuminates the ro
27 l of this study was to obtain the opinion of hematologists and medical oncologists about CD20-directe
28  2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville,
29                                              Hematologists and oncologists are uniquely suited to hel
30             Thus, this national survey of US hematologists and oncologists has identified substantial
31 s review provides a framework for practicing hematologists and oncologists to make rational treatment
32 al advisory committee (CAC) of international hematologists and oncologists was formed to ensure that
33                                              Hematologists and ophthalmologists should be aware of it
34 unication and shared decision-making between hematologists and patients, as well as program-building,
35 matopathologists, and more than 100 clinical hematologists and scientists who are internationally rec
36 CH) in older individuals has changed the way hematologists and stem cell biologists view aging.
37 future transfusions, remains a challenge for hematologists and transfusion medicine providers.
38 ns, intensivists, internists, pediatricians, hematologists, and transfusion medicine specialists.
39 d, 2 articles by The Nimes Obstetricians and Hematologists-Antiphospholipid Syndrome (NOH-APS) Study
40 well as autoimmune diseases mandate that all hematologists are familiar with these risks.
41 herosclerotic or cardioembolic etiology, but hematologists are frequently asked to assist in the diag
42                                     However, hematologists are in the unique position to diagnose AL
43 resentations of HHT-associated bleeding that hematologists are likely to encounter in daily practice.
44 heir experience of managing 4 scenarios that hematologists are likely to encounter in their day-to-da
45                                              Hematologists are often asked to treat patients with ven
46  failure in the pediatric patient places the hematologist at the junction of clinical medicine, cellu
47 nized under the microscope by the practicing hematologist because early institution of all-trans reti
48  Knowledge of these advances is relevant for hematologists because they administer the hematin infusi
49 levated biomarkers of organ involvement, and hematologists can screen subjects who have known monoclo
50 is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologis
51 be fully endorsed as risk classifiers by the hematologist community, further characterization of unde
52                   Stratton and the prominent hematologist Dr William Dameshek of Tufts School of Medi
53                                Benveniste, a hematologist, engineer, skeptic, statistician, neuroscie
54                        She was referred to a hematologist for evaluation of persistent isolated throm
55 mmonly bring the patient to the attention of hematologists for both evaluation and treatment.
56  leukemia (AML) has presented challenges for hematologists for decades.
57  Patients with celiac disease may present to hematologists for evaluation of various hematologic prob
58 r peculiar characteristics that have puzzled hematologists for more than a century.
59 has long fascinated biologists and attracted hematologists given its importance for patients with hem
60                                              Hematologists have a significant role in the diagnosis a
61                                    Moreover, hematologists have also noted that these children common
62 In addition to the severe beta thalassemias, hematologists have begun to recognize the more severe fo
63                               For a century, hematologists have comfortably understood that each type
64 chemists, cell and molecular biologists, and hematologists have provided an appreciation of the compl
65 986-2006 were confirmed by a panel of expert hematologists/hematopathologists.
66               Drawing on sources produced by hematologists, historian Keith Wailoo has shown that whe
67 e new recommendations especially relevant to hematologists in managing bleeding, anticoagulation, and
68  some of the variations in phenotype seen by hematologists in patients with identical mutations, to i
69                          Key issues faced by hematologists in this era of new drugs include (1) the t
70 rking group of obstetricians, nephrologists, hematologists, intensivists, neonatologists, and complem
71 f blood films and bone marrow aspirates by a hematologist is a crucial step in establishing diagnosis
72  present to various medical specialties, the hematologist is often consulted to offer the definitive
73                            A leading British hematologist, John V. Dacie was known for his pioneering
74                                           As hematologists make a diagnosis of anemia, which invites
75 f patients with unexplained cytopenia, which hematologists may encounter in their clinical practice.
76  will improve the diagnostic capabilities of hematologists, microbiologists, medical technologists, a
77 d thrombosis paradigms, while the practicing hematologist must appreciate platelet relevance in a wid
78 es evaluation by a multidisciplinary team (a hematologist, neurologist, neuroradiologist, and transfu
79    These developments are reviewed to update hematologists on the latest advances in these diverse di
80 tidisciplinary team including an experienced hematologist/oncologist, a high-risk obstetrics speciali
81  consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists.
82 dvisory committees composed of pathologists, hematologists, oncologists, and genomic scientists.
83 pathogen is warranted among rheumatologists, hematologists, oncologists, and infectious disease speci
84 zerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, patho
85 centage points; P = .007) and specialty (eg, hematologist-oncologists vs primary care, filgrastim: ad
86                    Currently, nephrologists, hematologist-oncologists, neurologists, and transplant s
87            Respondents were mostly pediatric hematologists-oncologists (PHOs) but included geneticist
88 16 725 for general internists to $40 495 for hematologists-oncologists.
89 atic sample of 5% of medical oncologists and hematologist/oncologists listed in the membership direct
90 tional call for surge capacity that involves hematologists/oncologists across the country in the disa
91 ts that would require extensive support from hematologists/oncologists across the country.
92  survivors return to the care of their local hematologists/oncologists or primary care physicians, wh
93 ciplinary panel of transplant nephrologists, hematologists/oncologists, and pathologists convened to
94  which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell trans
95 ogists, gynecologic oncologists, urologists, hematologists, pediatric oncologists, and surgeons) shou
96 agnostic efficacy is evaluated by a panel of hematologists performing a blind analysis of blood smear
97 of immune thrombocytopenic purpura, when the hematologist plays a consultative role, priority should
98 itutionally supported systems-based clinical hematologist positions that predominantly focus on nonma
99 to ensure sustainable professional roles for hematologists, reliable patient access to optimal hemato
100   Two hundred sixteen (5.0%) oncologists and hematologists responded to our survey.
101 mains among the most toxic treatments in the hematologist's armamentarium due to the combined risks o
102           There is variation in the clinical hematologist's role in thrombosis practice throughout th
103                               Accordingly, a hematologist's skills in understanding the importance an
104 en the blood bank, pharmacy, administration, hematologists, surgeon, and anesthesiologist to ensure t
105                    Despite the perception by hematologists that this disease has already been conquer
106 the diagnosis is intentional and credited to hematologists, the discovery of MGUS is most often incid
107  questions was sent to 4,239 oncologists and hematologists throughout the United States.
108 the bedside clinical team and the consulting hematologist to achieve prompt and targeted hemostatic r
109 mostasis, it is incumbent on the part of the hematologist to be able to carry out a logical clinical
110 aly management, will continue to require the hematologist to select therapeutic options carefully in
111 and radiographic clues that should alert the hematologist to the possibility of mucormycosis, and agg
112 often requires the involvement of consultant hematologists to assist with diagnosis and management of
113 ematopoiesis, including important points for hematologists to consider discussing with affected perso
114 ematologic malignancies, it is important for hematologists to effectively communicate with patients a
115 posed by transplant hepatologists, surgeons, hematologists, transplant-specialized anesthesiologists,
116 of issues and communication between clinical hematologists, transplantation physicians, and transfusi
117 concerns were that referring oncologists and hematologists wanted to treat by themselves with nonradi
118 ent and treatment options for the practicing hematologist, we propose elements of a new research agen
119                                           As hematologists, we must do more.
120  guide patients with sickle cell disease and hematologists who are considering allogeneic transplanta
121 arios was mailed to American oncologists and hematologists who practice medical oncology.
122                Among 112 medical oncologists/hematologists who responded to a survey about SDOH Z cod
123  provides interested scientists and clinical hematologists with a genome-based approach toward the st
124  zebrafish as a model organism have provided hematologists with an additional genetic system to study
125 nel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI

 
Page Top